A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07321951 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG: SHR-1819 Injection
DRUG: SHR-1819 Injection Blank Preparation

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd